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Copyright © 200? JCBN Summary Altered inflammatory immune responses have been shown to be associated with
functional gastro intestinal disorder. We aimed to clarify the effect of functional promoter
polymorphism of RANTES, which is a potent chemoattractant peptide for memory T lympho-
cytes and eosinophils, on the risk of functional dyspepsia in a Japanese population. RANTES
promoter C-28G polymorphism was genotyped in 246 subjects including 134 FD patients
according to Roma III criteria and 112 non-symptomatic healthy controls. Although frequency
of RANTES promoter polymorphisms in overall dyspeptic patients and non-symptomatic
healthy controls did not show any significant differences, a significant association was found
between G carrier and reduced risk of PDS according to Roma III criteria (age, sex, H. pylori
infection adjusted OR  = 0.23, 95% CI = 0.06–0.80). We also found that the same genotype
held a lower risk of PDS in H. pylori positive PDS subjects (age, sex adjusted OR = 0.11, 95%
CI = 0.01–0.94). Our data suggest that RANTES promoter -28G carriers is associate with a
reduced risk of PDS especially in H. pylori positive subjects.
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Introduction
Functional dyspepsia (FD) is clearly the commonest cause
of dyspeptic symptoms in the West and increasingly in other
parts of the world [1], affecting about 25% of the population
[2]. The latest definition of this includes the presence of
“chronic or recurrent symptoms centred in the upper abdomen
in the absence of any organic, systemic or metabolic disease
that is likely to explain the symptoms” [3]. FD is a hetero-
geneous condition indicated by the variety of different
pathophysiologic mechanisms that have been demonstrated
in this disorder [4], gastrointestinal motor abnormalities [5],
altered visceral sensation [6] and psychosocial factors [7]
have thought to be essential in the pathophysiology of FD.
There have been data indicating that abnormal inflammatory
immune response against various stimuli may be play a
major role in developing functional gastro intestinal disorder.
It has been reported that acute inflammation impairs nitergic
innervation [8], and cause gastrointestinal motor dysfunc-
tion [9]. Furthermore, positive association of irritable bowel
syndrome (IBS), FD between post infective condition has
been also reported [10, 11].
Helicobacter pylori (H. pylori) infection is a powerful
pathogenic factor and many studies have revealed a strong
association between this organism infection and gastric
disorders. H. pylori infection usually leads to chronic gastric
inflammation. According to the Roma III criteria [12], H.
pylori infected patients, who had some chronic or recurrent
upper abdominal symptoms, with neither ulceration norT. Tahara et al.
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erosion in gastroduodenal mucosa were also diagnosed as
FD. That is, there is a possibility that one of the FD sub-
groups may relate to the gastric mucosal inflammation
induced by H. pylori [13–15].
RANTES (short for “regulated upon activation, normal T
cell expressed and secreted”) is a member of the large and
growing family of immunoregulatory cytokines called
chemokines. RANTES belongs to the C-C chemokine sub-
family. It is a potent chemotactic agent for T lymphocytes
and monocytes [16] and is expressed after cellular activation
in fibroblasts, T cells, monocytes, endothelial cells, and
certain epithelial cells. RANTES has therefore been shown
to contribute to the infiltration of lymphocytes in the gastric
mucosa. Like that of IL-8, RANTES expression is increased
in  H. pylori infected gastric mucosa [17–19]. Persistent
expression and secretion of RANTES are also related to
residual infiltration of memory T lymphocytes for a pro-
longed period after H. pylori eradication [20].
Genetic studies on the RANTES gene have identified a
number of polymorphisms, including one that causes a
nucleotide substitution in promoter region, C-28G. The -28G
allele of the RANTES promoter was associated with higher
protein level than those of C allele [21].
Recent studies showed that RANTES promoter genotype
was associated with diabetic nephropathy in type 2 diabetic
subjects [22], late onset asthma [21] atopic dermatitis [23],
and progression of AIDS [24, 25].
Because the RANTES plays a major role in inflammatory
immune response in various condition, we hypothesized
that RANTES promoter polymorphism may influence the
susceptibility to FD. Here, we investigated the prevalence
of RANTES promoter C-28G polymorphism in patients with
FD accrding to Roma III in a Japanese population.
Materials and Methods
Study populations
We studied 246 subjects attending the Endoscopy Center
of Fujita Health University Hospital from January 2005 to
October 2007. The subjects underwent upper gastroscopy
for their health check, secondary complete check up of
stomach cancer following to barium X ray examination, or
for the complaint of abdominal discomfort. Subjects who
have significant upper gastrointestinal findings such as active
peptic ulcer disease, reflex esophagitis and malignancies
were excluded from this study. Patients with severe systemic
diseases, with malignancies in other organs, and had
received non-steroidal anti-inflamatory drugs, antibiotics,
and H. pylori eradication treatment were also excluded by
repeated face to face history and physical examination
including blood test, abdominal US and ECG. According to
the Roma III criteria, 134 FD patients were identified as
having a primary compliant of either continuous or inter-
mittent dyspepsia for 3 months, onset at least 6 months
before, predominantly located in upper abdomen irrespective
of using H2-receptor antagonists (H2RAS) or proton-pump
inhibitors (PPIS). Dyspeptic patients were also classified as
epigastric pain syndrome (EPS) and postprandial syndrome
(PDS) and others according to Roma III criteria. Subjects
who were negative by upper gastroscopy and negative for
dyspeptic symptom with in last 12 months were considered
as non-dyspeptic healthy controls. Those who had received
proton-pump inhibitory drugs or H2RAS during the 4 week
were excluded from healthy controls. The Ethics Committee
of Fujita Health University School of Medicine approved the
protocol and written informed consent was obtained from all
of the subjects.
Detection of H. pylori infection
The H. pylori infection status was determined on the basis
of histology, culture, the urease breath test (UBT), and
antibodies to H. pylori. Infection was diagnosed when at
least one of these 4 tests was positive.
Genotyping for RANTES promoter
Genomic DNA was extracted from non-neoplastic gastric
biopsies or peripheral blood using the standard phenol/
choloroform method. Then, the polymorphisms of -28 C/G
in the RANTES gene promoter region was investigated by
PCR-based RFLP assays as previously described [21].
Statistical analysis
Hardy-Weinberg equilibrium of the RANTES promoter
allele in the non-dyspeptic healthy controls and FD patients
were assessed by χ2 statistics. Differences of RANTES
promoter genotype frequencies between two groups were
determined by the two-sided Fisher’s exact test. The odds
ratio (OR) and 95% confidence interval (CI) were also
calculated. A probability value of less than 0.05 was consid-
ered statistically significant in all analyses.
Results
Study population
The characteristics of the subjects are summarized in
Table 1. Age distribution and H. pylori infection positive ratio
were not significantly different among those two groups.
Meanwhile, female sex ratio was significantly higher in the
dyspeptic patients than those of non-symptomatic healthy
controls. Of all 134 FD patients 70 subjects and 41 subjects
were diagnosed as EPS and PDS, respectively. The 70 EPS
and 41 PDS patients contained 9 subjects, who were
diagnosed as both PDS and EPS. Other 32 subjects were
diagnosed as other dyspepsia.RANTES Polymorphism in Dyspepsia
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Prevalence of RANTES promoter polymorphism in FD and
control subjects
RANTES genotypes in the non-symptomatic healthy
controls and FD patients did not deviate significantly from
those expected under the Hardy–Weinberg equilibrium
(p = 0.19, 0.98, respectively). In the non-symptomatic
healthy controls, RANTES promoter genotype distribution
was 84CC (75.0%), 24CG (21.4%), and 4GG (3.6%).
Meanwhile, the RANTES promoter distribution in FD
patients was 103CC (76.9%), 29CG (21.6%), and 2GG
(1.5%). Because frequency of GG genotype was low, we
considered CG and GG as G carrier and assessed the
association between genotype frequency and risk of FD.
Compared to healthy controls, frequencies of RANTES
promoter polymorphisms in overall dyspeptic patients did
not show any significant differences. Meanwhile, a signifi-
cant association was found between G carrier and reduced
risk of PDS according to Roma III criteria by Fisher’s exact
test (OR = 0.27, 95%CI = 0.07–0.83, p = 0.02; Table 2).
To further evaluate whether the RANTES promoter geno-
types might influence the risk of FD, we also investigated
the differences in RANTES promoter genotype frequencies
between different H. pylori infection status and gender
(Table 3). We found that the G carrier held a lower risk of
PDS in H. pylori positive subjects (OR = 0.12, 95%CI =
0.02–0.99, p = 0.03).
Logistic regression analysis
Logistic regression analysis with adjustment for age and
H. pylori infection status or gender was done for all PDS
as well as H. pylori positive PDS subjects. It was revealed
that the significant association of the RANTES promoter
-28G carriers with all PDS and H. pylori positive PDS
subjects were remained after logistic regression analysis
(all PDS; age, sex, H. pylori infection adjusted OR = 0.23,
95%CI = 0.06–0.80, p = 0.02, H. pylori positive PDS; age,
sex adjusted OR = 0.11, 95% CI = 0.01–0.94, p = 0.04).
Discussion
Recent evidence supports the relevance of a genetic
milieu in FD. A case-control study by Holtmann et al.
suggested that there is a significant link between GNβ3
(C825T) CC genotype and functional dyspepsia [26]. The
association has been independently confirmed [27]. However,
there are few reports demonstrated the relationship between
the polymorphisms of molecules associated with inflam-
mation and FD.
In the present study, we investigated the prevalence of
RANTES promoter polymorphism in dyspeptic patients in a
Japanese population. The -28G carrier was associated with
a reduced risk of PDS according to Rome III criteria.
Concerning the association between inflammatory immune
response and functional gastrointestinal disorder, it has been
reported that acute inflammation impairs nitergic innerva-
tion [8], and cause gastrointestinal motor dysfunction [9].
Positive association of irritable bowel syndrome (IBS), FD
between post infective condition has been also documented
[10, 11], suggesting that abnormal inflammatory immune
response may be one of the major pathogenesis of functional
gastro intestinal disorder.
RANTES is a powerful chemotactic agent for T lympho-
Table 1. Characteristics of subjects
#; FD vs Control, p = 0.007 (two-sided Fisher’s exact test)
FD (n = 134) Control (n =1 1 2 )
Age (mean SD) 60.1 ± 12.8 59.0 ± 13.9
Sex (male/female)# 59/75 69/43
H. pylori infection positive ratio (%) 53.7 58.9
Table 2. RANTES promoter polymorphism and risk of FD
Note; G carriers, GG + CG. Statistical analysis was performed by two-sided Fisher’s exact test. The 70 EPS and 41 PDS
patients contained 9 subjects, who were diagnosed as both PDS and EPS.
Variables; n (%) genotype/n(%) OR (95%CI) p
CC CG GG Gcarrier vs CC
Control (112) 84 (75.0) 24 (21.4) 4 (3.6) Reference
Over all FD (134) 103 (76.9) 29 (21.6) 2 (1.5) 0.61 (0.32–1.15) 0.77
EPS (70) 48 (68.6) 20 (28.6) 2 (2.8) 1.38 (0.71–2.66) 0.39
PDS (41) 38 (92.7) 3 (7.3) 0 (0) 0.24 (0.07–0.83) 0.02
Others (32) 24 (75) 8 (25) 0 (0) 1.00 (0.40–2.48) 1.00T. Tahara et al.
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cytes and monocytes [16]. Therefore, RANTES has also been
shown to contribute to the inflammatory response in the
stomach especially for H. pylori-induced gastritis [17–20].
Changes in gene expression in human monocytes after
stimulation of RANTES have been examined by the oligo-
nucleotide array method, showing that RANTES activates
the transcription of cytokine genes (MCP-1, pro interleukin-
1β, IL-8, eta.), membrane receptors (oxidized LDL receptor,
etc.), regulators of extracellular matrix proteins (MMP-9
etc.), and enzymes regulating intracellular signal transduc-
tion (MAPK, etc.) [28]. Four binding sites for nuclear
factor-κB in the RANTES promoter are critical for induction
by the proinflammatory cytokines tumor necrosis factor-α
and interleukin-1β and induction through the CD28
costimulatory pathway [29]. The RANTES promoter C-28G
polymorphism is located immediately downstream of the
first of these nuclear factor-κB sites (−40 to −31). Recent
reports show quantitative differences in RANTES protein
expression between different RANTES promoter genotypes
[21]. Although we did not investigate the serum or gastric
mucosal RANTES expression in FD patients, it is possible
that RANTES promoter genotypes would also influence the
inflammatory immune response in the gastrointestinal tract,
and therefore modify the risk of FD.
We have also shown that the -28 G carrier is associated
with a reduced risk of PDS in H. pylori infected subjects.
It is well known that H. pylori plays a major role in the
pathogenesis of gastro-duodenal inflammation. H. pylori
infection has also been reported to be more frequent in
patients with non-ulcer dyspepsia than control population,
although the role of H. pylori infection in functional dys-
pepsia is still controversial [30]. Many trials evaluating the
efficacy of H. pylori eradication treatment for FD have given
conflicting results but there is a clear indication that H.
pylori eradication treatment is effective in at least a subset of
patients with FD. The recently published meta-analysis
Table 3. RANTES promoter genotypes and risk of FD in different gender and H. pylori infection status
Note; G carriers, GG + CG. Statistical analysis was performed by two-sided Fisher’s exact test. The Hp(−) FD patients
contained 7 subjects, who were diagnosed as both PDS and EPS. The Hp(+) FD patients contained 2 subjects, who were
diagnosed as both PDS and EPS. The male FD patients contained 3 subjects, who were diagnosed as both PDS and EPS.
The female FD patients contained 5 subjects, who were diagnosed as both PDS and EPS.
Variables; n genotype/n OR (95% CI)p
CC CG GG Gcarrier vs CC
Hp(−)
Control (46) 37 9 0 Reference
Over all FD (62) 52 9 1 0.79 (0.29–2.14) 0.80
EPS (38) 29 8 1 1.28 (0.45–3.62) 0.79
PDS (20) 18 2 0 0.46 (0.09–2.34) 0.48
Others (11) 11 0 0 ND
HP(+)
Control (66) 47 15 4 Reference
Over all FD (72) 51 20 1 1.02 (0.49–2.13) 1.00
EPS (32) 19 12 1 1.13 (0.42–3.06) 0.80
PDS (21) 20 1 0 0.12 (0.02–0.99) 0.03
Others (21) 13 8 0 1.52 (0.54–4.26) 0.43
Male
Control (69) 54 14 1 Reference
Over all FD (59) 51 7 1 0.56 (0.22–1.44) 0.26
EPS (33) 28 4 1 0.64 (0.21–1.95) 0.60
PDS (19) 18 1 0 0.20 (0.02–1.62) 0.18
Others (10) 8 2 0 0.90 (0.17–4.69) 1.00
Female
Control (43) 30 10 3 Reference
Over all FD (75) 52 22 1 1.02 (0.45–2.30) 1.00
EPS (37) 20 16 1 1.96 (0.78–4.91) 0.17
PDS (22) 20 2 0 0.23 (0.05–1.13) 0.07
Others (22) 16 6 0 0.87 (0.28–2.71) 1.00RANTES Polymorphism in Dyspepsia
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suggests that H. pylori eradication at 12 months has a small
but statistically significant benefit in the treatment of FD
[31]. Depending on the population under study, between
30%–65% of patients diagnosed with functional dyspepsia
has  H. pylori-induced gastritis [32,  33]. These studies
suggest that H. pylori-induced gastric mucosal inflammation
may play an important role on the pathophysiology of FD.
Increased RANTES production is a feature of H. pylori
induced gastric inflammation [17–20]. RANTES mRNA
expression is also thought to play an important role in
maintaining residual memory T lymphocytes and eosino-
phils in gastric mucosa following H. pylori eradication [20].
Our data indicate that RANTES polymorphism may modify
the risk of H. pylori infected FD by altering the inflam-
matory response against H. pylori.
In the functionl perspective, -28G allele of the RANTES
promoter have shown to have the higher level of mRNA and
protein expression than those of C allele [21]. In our study,
high producing genotype of -28G carriers was reduced the
risk of PDS especially in H. pylori infected subjects. It is
possible that altered immune response against H. pylori by
RANTES promoter polymorphism may alter the inflam-
matiory immune response. But why the high producing
genotype of -28G carriers reduced the risk of PDS is
remained to be explained.
Abbreviations
FD, functional dyspepsia; H. pylori, Helicobacter pylori;
EPS, epigastric pain syndrome; PDS, postprandial syndrome.
References
[1] Locke, G.R. 3rd.: Prevalence, incidence and natural history
of dyspepsia and functional dyspepsia. Ballieres. Clin.
Gastroenterol., 123, 435–442, 1998.
[2] Talley, N.J., Zinsmeister, A.R., Schleck, CD., and Melton,
L.J. 3rd.: Dyspepsia and dyspepsia subgroups: a population-
based study. Gastroenterology, 102, 1259–1268, 1992.
[3] Tack, J., Talley, N.J., Camilleri, M., Holtmann, G., Hu, P.,
Malagelada, J.R., and Stanghellini, V.: Functional gastro-
duodenal disorders. Gastroenterology,  130, 1466–1479,
2006.
[4] Tack, J., Bisschops, R., and Sarnelli, G.: Pathophysiology and
treatment of fuctional dyspepsia. Gastroenterology,  127,
1239–1255, 2004.
[5] Tack, J., Piessevaux, H., Coulie, B., Caenepeel, P., and
Janssens, J.: Role of impaired gastric accommodation to a
meal in functional dyspepsia. Gastroenterology, 115, 1346–
1352, 1998.
[6] Lunding, J.A., Tefera, S., Gilja, O.H., Hausken, T., Bayati,
A., Rydholm, H., Mattsson, H., and Berstad, A.: Rapid initial
gastric emptying and hypersensitivity to gastric filling in
functional dyspepsia: effects of duodenal lipids. Scand. J.
Gastroenterol., 41, 1028–1036, 2006.
[7] Chen, T.S., Lee, Y.C., Chang, F.Y., Wu, H.C., and Lee, S.D.:
Psychosocial distress is associated with abnormal gastric
myoelectrical activity in patients with functional dyspepsia.
Scand. J. Gastroenterol., 41, 791–796, 2006.
[8] Mizuta, Y., Isomoto, H., and Takahashi, T.: Impaired nitergic
innervation in rat colitis induced by dextran sulfate sodium.
Gastroenterology, 118, 714–723, 2000.
[9] Pennazio, M., Santucci, R., Rondonotti, E., Abbiati, C.,
Beccari, G., Rossini, FP., and De Franchis, R.: Outcome of
patients with obscure gastrointestinal bleeding after capsule
endoscopy: report of 100 consecutive cases. Gastroenterology,
126, 643–653, 2004.
[10] Tack, J., Demedts, I., Dehondt, G., Caenepeel, P., Fischler,
B., Zandecki, M., and Janssens, J.: Clinical and pathophysio-
logical characteristics of acute-onset functional dyspepsia.
Gastroenterology, 122, 1738–1747, 2002.
[11] Spiller, R.C.: Postinfectious irritable bowel syndrome.
Gastroenterology, 124, 1662–1671, 2003.
[12] Tack, J., Talley, N.J., Camilleri, M., Holtmann, G., Hu, P.,
Malagelada, J.R., and Stanghellini, V.: Functional gastro-
duodenal disorders. Gastroenterology,  130, 1466–1479,
2006.
[13] Stanghellini, V., Ghidini, C., Maccarini, M.R., Paparo, G.F.,
Corinaldesi, R., and Barbara, L.: Fasting and postprandial
gastrointestinal motility in ulcer and non-ulcer dyspepsia.
Gut, 33, 84–90, 1992.
[14] Scott, A.M., Kellow, J.E., Shuter, B., Cowan, H., Corbett,
A.M., Riley, J.W., Lunzer, M.R., Eckstein, R.P., Höschl, R.,
and Lam, S.K.: Intragastric distribution and gastric emptying
of solids and liquids in functional dyspepsia. Dig. Dis. Sci.,
38, 2247–2254, 1993.
[15] Jian, R., Ducrot, F., Ruskone, A., Chaussade, S., Rambaud,
J.C., Modigliani, R., Rain, J.D., and Bernier, J.J.: Sympto-
matic, radionuclide and therapeutic assessment of chronic
idiopathic dyspepsia. A double-blind placebo controlled
evaluation of cisapride. Dig. Dis. Sci., 34, 657–664, 1989.
[16] Schall, T.J., Bacon, K., Toy, K.J., and Goeddel, D.V.: Selec-
tive attraction of monocytes and T lymphocytes of the
memory phenotype by cytokine RANTES. Nature, 347, 669–
671, 1990.
[17] Cottet, S., Corthésy-Theulaz, I., Spertini, F., and Corthésy,
B.: Microaerophilic conditions permit to mimic in vitro
events occurring during in vivo Helicobacter pylori infection
and to identify Rho/Ras-associated proteins in cellular signal-
ing. J. Biol. Chem., 277, 33978–33986, 2002.
[18] Shimoyama, T., Everett, S.M., Dixon, M.F., Axon, A.T., and
Crabtree, J.E.: Chemokine mRNA expression in gastric
mucosa is associated with Helicobacter pylori cagA positivity
and severity of gastritis. J. Clin. Pathol., 51, 765–770, 1998.
[19] Yamaoka, Y., Kita, M., Kodama, T., Sawai, N., Tanahashi, T.,
Kashima, K., and Imanishi, J.: Chemokines in the gastric
mucosa in Helicobacter pylori infection. Gut, 42, 609–617,
1998.
[20] Kikuchi, T., Kato, K., Ohara, S., Sekine, H., Arikawa, T.,
Suzuki, T., Noguchi, K., Saito, M., Saito, Y., Nagura, H.,
Toyota, T., and Shimosegawa, T.: The relationship betweenT. Tahara et al.
J. Clin. Biochem. Nutr.
240
persistent secretion of RANTES and residual infiltration of
eosinophils and memory T lymphocytes after Helicobacter
pylori eradication. J. Pathol., 192, 243–250, 2000.
[21] Hizawa, N., Yamaguchi, E., Konno, S., Tanino, Y., Jinushi,
E., and Nishimura, M.: A functional polymorphism in the
RANTES gene promoter is associated with the development
of late-onset asthma. Am. J. Respir. Crit. Care Med., 166,
686–690, 2002.
[22] Nakajima, K., Tanaka, Y., Nomiyama, T., Ogihara, T., Ikeda,
F., Kanno, R., Iwashita, N., Sakai, K., Watada, H., Onuma,
T., and Kawamori, R.: RANTES promoter genotype is
associated with diabetic nephropathy in type 2 diabetic
subjects. Diabetes Care, 26, 892–898, 2003.
[23] Nickel, R.G., Casolaro, V., Wahn, U., Beyer, K., Barnes,
K.C., Plunkett, B.S., Freidhoff, L.R., Sengler, C., Plitt, J.R.,
Schleimer, R.P., Caraballo, L., Naidu, R.P., Levett, P.N.,
Beaty, T.H., and Huang, S.K.: Atopic dermatitis is associated
with a functional mutation in the promoter of the C-C
chemokine RANTES. J. Immunol., 164, 1612–1616, 2000.
[24] Liu, H., Chao, D., Nakayama, E.E., Taguchi, H., Goto, M.,
Xin, X., Takamatsu, J.K., Saito, H., Ishikawa, Y., Akaza, T.,
Juji, T., Takebe, Y., Ohishi, T., Fukutake, K., Maruyama, Y.,
Yashiki, S., Sonoda, S., Nakamura, T., Nagai, Y., Iwamoto,
A., and Shioda, T.: Polymorphism in RANTES chemokine
promoter affects HIV-1 disease progression. Proc. Natl.
Acad. Sci. USA, 96, 4581–4585, 1999.
[25] McDermott, D.H., Beecroft, M.J., Kleeberger, C.A., Al-
Sharif, F.M., Ollier, W.E., Zimmerman, P.A., Boatin, B.A.,
Leitman, S.F., Detels, R., Hajeer, A.H., and Murphy, P.M.:
Chemokine RANTES promoter polymorphism affects risk of
both HIV infection and disease progression in the Multi-
center AIDS Cohort Study. AIDS, 14, 2671–2678, 2000.
[26] Holtmann, G., Siffert, W., Haag, S., Mueller, N., Langkafel,
M., Senf, W., Zotz, R., and Talley, N.J.: G-protein beta 3
subunit 825 CC genotype is associated with unexplained
(functional) dyspepsia. Gastroenterology,  126, 971–979,
2004.
[27] Camilleri, C.E., Carlson, P.J., Camilleri, M., Castillo, E.J.,
Locke, G.R., Geno, D.M., Stephens, D.A., Zinsmeister, A.R.,
and Urrutia, R.: A study of candidate genotypes associated
with dyspepsia in a U.S. community. Am. J. Gastroenterol.,
101, 581–592, 2006.
[28] Locati, M., Deuschle, U., Massardi, M.L., Martinez, F.O.,
Sironi, M., Sozzani, S., Bartfai, T., and Mantovani, A.:
Analysis of the gene expression profile activated by the CC
chemokine ligand 5/RANTES and by lipopolysaccharide in
human monocytes. J. Immunol., 168, 3557–3562, 2002.
[29] Moriuchi, H., Moriuchi, M., and Fauci, A.S.: Nuclear factor-
kappa B potently up-regulates the promoter activity of
RANTES, a chemokine that blocks HIV infection. J.
Immunol., 158, 3483–3491, 1997.
[30] McColl, K., Murray, L., El-Omar, E., Dickson, A., El-
Nujumi, A., Wirz, A., Kelman, A., Penny, C., Khill-Jones,
R., and Hilditch, T.: Symptomatic benefit from eradicating
Helicobacter pylori infection in patients with nonulcer dys-
pepsia. N. Engl. J. Med., 339, 1869–1874, 1998.
[31] Moayyedi, P., Deeks, J., Talley, N.J., Delaney, B., and
Forman, D.: An update of the Cochrane systematic review of
Helicobacter pylori eradication therapy in nonulcer dyspepsia:
resolving the discrepancy between systematic reviews. Am.
J. Gastroenterol., 98, 2621–2626, 2003.
[32] Talley, N.J.: Helicobacter pylori and non-ulcer dyspepsia.
Scand. J. Gastroenterol., 220, 19–22, 1996.
[33] Armstrong, D.: Helicobacter pylori infection and dyspepsia.
Scand. J. Gastroenterol. Suppl., 215, 38–47, 1996.